
    
      Extensive-stage small cell lung carcinoma is incurable. Present therapies are toxic and
      responses are short lived. This phase II, single arm, window of opportunity study will assess
      the response rate and toxicity of pemetrexed and gemcitabine in this cohort.
    
  